Home » ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models

To read the full story, subscribe or sign in.

Immuno-oncology

ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models

June 5, 2024

Hangzhou Adcoris BioPharma Co. Ltd. is developing ACR-246, a novel 5T4-targeted antibody-drug-conjugate (ADC), for the treatment of solid tumors.

BioWorld Science Conferences American Society of Clinical Oncology Cancer Antibody-drug conjugate Immuno-oncology